Placebo to Baloxavir Marboxil

DRUG2 trials

Sponsors

Shionogi

Conditions

Influenza

Phase 3

Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications

CompletedNCT02949011

ShionogiInfluenza

Start: 2017-01-11End: 2018-04-20Updated: 2019-11-19

A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza

CompletedNCT02954354

ShionogiInfluenza

Start: 2016-12-08End: 2017-04-24Updated: 2019-05-08

Related Papers

Safety and Efficacy of Baloxavir Marboxil in Influenza-infected Children 5–11 Years of Age: A Post Hoc Analysis of a Phase 3 Study

The Pediatric Infectious Disease Journal2023-08-1712 citations

A Pharmacokinetics–Time to Alleviation of Symptoms Model to Support Extrapolation of Baloxavir Marboxil Clinical Efficacy in Different Ethnic Groups with Influenza A or B

Clinical Pharmacology & Therapeutics2022-05-193 citations

Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial.

2020-06-08186 citations

Treatment-Emergent Influenza Variant Viruses With Reduced Baloxavir Susceptibility: Impact on Clinical and Virologic Outcomes in Uncomplicated Influenza

The Journal of Infectious Diseases2019-05-09189 citations

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents

New England Journal of Medicine2018-09-05878 citations